全文获取类型
收费全文 | 36842篇 |
免费 | 2321篇 |
国内免费 | 490篇 |
专业分类
耳鼻咽喉 | 322篇 |
儿科学 | 848篇 |
妇产科学 | 707篇 |
基础医学 | 4474篇 |
口腔科学 | 999篇 |
临床医学 | 4064篇 |
内科学 | 7114篇 |
皮肤病学 | 549篇 |
神经病学 | 3217篇 |
特种医学 | 1442篇 |
外科学 | 4232篇 |
综合类 | 1313篇 |
一般理论 | 31篇 |
预防医学 | 3379篇 |
眼科学 | 903篇 |
药学 | 3204篇 |
1篇 | |
中国医学 | 356篇 |
肿瘤学 | 2498篇 |
出版年
2023年 | 197篇 |
2022年 | 326篇 |
2021年 | 684篇 |
2020年 | 454篇 |
2019年 | 639篇 |
2018年 | 699篇 |
2017年 | 586篇 |
2016年 | 607篇 |
2015年 | 779篇 |
2014年 | 1116篇 |
2013年 | 1685篇 |
2012年 | 2371篇 |
2011年 | 2507篇 |
2010年 | 1437篇 |
2009年 | 1404篇 |
2008年 | 2315篇 |
2007年 | 2646篇 |
2006年 | 2568篇 |
2005年 | 2480篇 |
2004年 | 2353篇 |
2003年 | 2240篇 |
2002年 | 2156篇 |
2001年 | 436篇 |
2000年 | 340篇 |
1999年 | 449篇 |
1998年 | 553篇 |
1997年 | 490篇 |
1996年 | 439篇 |
1995年 | 405篇 |
1994年 | 364篇 |
1993年 | 314篇 |
1992年 | 200篇 |
1991年 | 220篇 |
1990年 | 197篇 |
1989年 | 204篇 |
1988年 | 169篇 |
1987年 | 161篇 |
1986年 | 144篇 |
1985年 | 176篇 |
1984年 | 229篇 |
1983年 | 178篇 |
1982年 | 255篇 |
1981年 | 262篇 |
1980年 | 240篇 |
1979年 | 116篇 |
1978年 | 112篇 |
1977年 | 119篇 |
1976年 | 95篇 |
1975年 | 79篇 |
1974年 | 70篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Melanie A. Krook Julie W. Reeser Gabrielle Ernst Hannah Barker Max Wilberding Gary Li Hui-Zi Chen Sameek Roychowdhury 《British journal of cancer》2021,124(5):880
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer 相似文献
2.
3.
4.
5.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
6.
7.
Phytonutrients extracted from natural resources are receiving much attention among researchers due to their highly antioxidative characteristics which prevent several degenerative diseases including cardiovascular diseases and cancers. These nutraceutical compounds can be used in food, pharmaceutical and cosmetic products as natural antioxidants, preservatives, colourants and functional foods. Huge volume of food wastes are generated from the processing industry and these low-value food residues are rich in various phytonutrients worth recovering. This approach of valorisation reduces the generation of food wastes and is cost-effective considering the cheap feedstock, reduced waste management expenses and high market value of extracted compounds. In light of the health and safety risks posed by commonly used organic extraction solvents derived from the petrochemical industry, there is a need to recover the phytonutrients using green, sustainable and efficient solvents that are safe for human consumption. This work discusses ethyl lactate as a safe, green, efficient and potentially cheap solvent to recover phytonutrients from fruit and vegetable by-products. Ethyl lactate is compared with other organic solvents commonly used from the aspects of safety, environmental impacts and efficiency. Current challenges when employing ethyl lactate are also discussed. 相似文献
8.
Gregory N. Gan 《Expert opinion on investigational drugs》2016,25(10):1153-1166
Introduction: Cancer treatment is moving away from conventional cytotoxic drugs and towards agents that target specific proteins and mechanisms important to cancer development or survival. The Hedgehog Pathway (HhP) is a signal transduction pathway and its constitutive activation is tumorigenic in basal cell carcinoma (BCC). The HhP enables phenotypic flexibility, and channels tumor-stroma interactions. As a result, it is over-expressed in numerous cancers as well as in the tumor microenvironment and may represent a promising therapeutic target.Areas covered: In this article, we review the rationale for targeting HhP and its role as an oncogenic driver, in tumor epithelial-to-mesenchymal transition (EMT), and in the tumor microenvironment and describe the results of preclinical and clinical studies involving HhP inhibitors.Expert opinion: HhP activation plays an important role in both the tumor microenvironment and tumor EMT which can lead to treatment resistance for a number of different malignancies. In addition to standard use in BCC, several HhP inhibitors are in preclinical, early, and mid-stage clinical development for other solid and hematologic malignancies. 相似文献
9.
10.